
Celcuity (CELC) Stock Forecast & Price Target
Celcuity (CELC) Analyst Ratings
Bulls say
Celcuity Inc. has demonstrated significant stock appreciation of approximately 608% year-to-date, outperforming major indices, which underscores strong investor interest and confidence in the company's potential. The positive outlook is bolstered by promising clinical trial results for gedatolisib, with improved safety profiles reported in the ongoing Phase 3 VIKTORIA-1 trial and an increased probability of launch raised to 90%. Additionally, with raised sales estimates reflecting expedited regulatory pathways and market potential, the financial projections for gedatolisib have also been adjusted upward, indicating an expansive opportunity for revenue generation in the oncology market.
Bears say
Celcuity Inc. is currently facing a negative outlook primarily due to concerns about its financial position, highlighted by a significant estimated R&D spend of $35 million, which, despite being down 13% sequentially, raises questions about the company's cash management in a clinical stage. The FDA's acceptance of the NDA application for gedatolisib offers potential upside; however, any delays in the anticipated approval timeline could adversely impact market sentiment and stock performance. Furthermore, potential competition from larger pharmaceutical companies and the risk of lower-than-expected pricing power due to higher discounts from payors contribute to the cautious sentiment surrounding Celcuity's valuation at $4.3 billion, leading to a recommendation for investors to remain cautious.
This aggregate rating is based on analysts' research of Celcuity and is not a guaranteed prediction by Public.com or investment advice.
Celcuity (CELC) Analyst Forecast & Price Prediction
Start investing in Celcuity (CELC)
Order type
Buy in
Order amount
Est. shares
0 shares